Fundraising Fox
OpGen
Gaithersburg, US · Delaware corporation · 4 known investors
Find your way into OpGen
Sign up to see every warm intro you have to OpGen
- Paths you didn't know you had: your email and LinkedIn already hold routes to the OpGen team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
The page announces the launch of a new fintech arm called CapForce. No further detail about the company's core business is provided on the page.
Founders & leadership
EJ
Evan JonesFounder
VS
Vadim SapiroExecutiveVadim Sapiro is an executive officer at OpGen with over 25 years of experience in IT and biotechnology leadership, including work on bioinformatics solutions, clinical IT, and diagnostics. His background spans digital strategy, life sciences commercialization, IT architecture, and regulatory compliance in healthcare and R&D environments.
CE
C. Eric WinzerExecutive
DH
David HoekzemaExecutiveDavid Hoekzema is an executive in life sciences with 35 years of industry experience. He has worked in business development, strategic management, and commercial operations, and has held consulting engagements with biotech firms and in federal R&D contracting.
TW
Terry WalkerExecutive
CD
C. Douglas WhiteExecutive
Board
BG
Brian G. AtwoodBoard director
BS
Bijan SalehizadehBoard director
RW
Ronald W. LennoxBoard director
CM
MU
Misti UshioBoard director
TH
Timothy HoweBoard director
Investors · 4
Cross Creek Advisorslisted by Cross Creek AdvisorsSalt Lake City
How we know: Cross Creek Advisors's portfolio page · Not right? Tell us
In-Q-Tellisted by In-Q-TelTysons · $100K – $2.5M
How we know: In-Q-Tel's portfolio page · Not right? Tell us
Digitalis VenturesinferredNew York · $100K – $10M
How we know: board seat on SEC Form D · Not right? Tell us
Highland Capital PartnersreportedCambridge · $1M – $10M
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$65M disclosed across 13 of 14 rounds · 2011–2024
▶$3.4MraisedOct 2022 · 1 investors · BiotechnologyRule 506(b)
▶$3.4MraisedOct 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Johannes BacherExecutive Officer
- William E. Rhodes IIIDirector
- Prabhavathi FernandesDirector
- R. Donald ElseyDirector
- Mario CrovettoDirector
- Albert WeberExecutive Officer
- Oliver SchachtExecutive Officer, Director
- Offering amount
- $3.4M
- Amount sold
- $3.4M
- Sales commissions
- $202.9K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Oct 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$25MraisedFeb 2021 · 1 investors · BiotechnologyRule 506(b)
▶$25MraisedFeb 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- William E. Rhodes IIIDirector
- Mario CrovettoDirector
- Oliver SchachtExecutive Officer
- Evan JonesDirector
- Prabhavathi FernandesDirector
- Johannes BacherExecutive Officer
- Timothy C. DecExecutive Officer
- R. Donald ElseyDirector
- Offering amount
- $25M
- Amount sold
- $25M
- Sales commissions
- $1.5M
- Placement agents
- Alliance Global Partners
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedDec 2020 · 1 investors · BiotechnologyRule 506(b)
▶$10MraisedDec 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Johannes BacherExecutive Officer
- Oliver SchachtExecutive Officer
- Evan JonesDirector
- R. Donald ElseyDirector
- Prabhavathi FernandesDirector
- William E Rhodes IIIDirector
- Mario CrovettoDirector
- Timothy C DecExecutive Officer
- Offering amount
- $10M
- Amount sold
- $10M
- Sales commissions
- $648.3K
- Placement agents
- Alliance Global Partners
- First sale
- Nov 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$285.5KraisedAug 2018 · 1 investors · BiotechnologyRule 506(b)
▶$285.5KraisedAug 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Harry D'AndreaDirector
- David M RubinDirector
- Timothy C DecExecutive Officer
- Timothy J.R. HarrisDirector
- Tina S NovaDirector
- Evan JonesExecutive Officer, Director
- Misti UshioDirector
- Offering amount
- $285.5K
- Amount sold
- $285.5K
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$110KraisedSep 2017 · 1 investors · BiotechnologyRule 506(b)
▶$110KraisedSep 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Harry D'AndreaDirector
- Tina S NovaDirector
- David M RubinDirector
- Timothy C DecExecutive Officer
- Timothy J.R. HarrisDirector
- Evan JonesExecutive Officer, Director
- Misti UshioDirector
- Offering amount
- $110K
- Amount sold
- $110K
- First sale
- Sep 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$500KraisedJun 2017 · 2 investors · BiotechnologyRule 506(b)
▶$500KraisedJun 2017 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David M RubinDirector
- Misti UshioDirector
- Tina S NovaDirector
- Harry D'AndreaDirector
- Timothy J.R. HarrisDirector
- Evan JonesExecutive Officer, Director
- Timothy C DecExecutive Officer
- Offering amount
- $1.5M
- Amount sold
- $500K
- First sale
- Jun 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.2MraisedMay 2016 · 10 investors · BiotechnologyRule 506(b)
▶$7.2MraisedMay 2016 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Timothy C DecExecutive Officer
- Timothy HoweDirector
- Kevin KrenitskyExecutive Officer
- Timothy J.R. HarrisDirector
- Evan JonesExecutive Officer, Director
- Brian G AtwoodDirector
- David M RubinDirector
- Misti UshioDirector
- Laurence R McCarthyDirector
- Harry D'AndreaDirector
- Offering amount
- $10.4M
- Amount sold
- $7.2M
- Sales commissions
- $694.9K
- Placement agents
- Leerink Partners LLC, Maxim Group LLC, Cowen and Company
- First sale
- May 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.6MraisedJul 2015 · 4 investors · BiotechnologyRule 506(b)
▶$2.6MraisedJul 2015 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Evan JonesExecutive Officer, Director
- Kevin KrenitskyExecutive Officer
- Misti UshioDirector
- Timothy J.R. HarrisDirector
- Laurence R McCarthyDirector
- Vadim SapiroExecutive Officer
- Timothy HoweDirector
- Brian G AtwoodDirector
- David M RubinDirector
- Timothy C DecExecutive Officer
- Offering amount
- $2.6M
- Amount sold
- $2.6M
- First sale
- Jul 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 10
AmgenAmgen is an independent biotechnology company that uses science and technology, including machine learning and human genetic data, to research and develop treatments for serious diseases such as cancer, heart disease, asthma, and osteoporosis. Its Danish operation, Amgen Danmark, focuses on improving health outcomes for patients and their families in Denmark.
Biogen IdecBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.
PepGenPepGen is a clinical-stage biotech company developing oligonucleotide therapies for neuromuscular and neurological diseases using its Enhanced Delivery Oligonucleotide (EDO) platform to improve tissue penetration and uptake in muscle tissues.
PublicPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Simply Wall StSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
WugenAllotera (formerly Wugen) develops allogeneic T-cell therapies. The company focuses on cell and gene therapy approaches for treating disease.
UrogenUroGen is a biotech company developing treatments for urothelial and specialty cancers using a proprietary sustained-release hydrogel platform technology. The company commercializes approved therapies for bladder and upper tract cancers, with additional candidates in development.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
TradingViewTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Companies working in the same space as OpGen.
Frequently asked questions
- What does OpGen do?
- The page announces the launch of a new fintech arm called CapForce. No further detail about the company's core business is provided on the page.
- Who founded OpGen?
- OpGen was founded by Evan Jones.
- Who are OpGen's investors?
- OpGen's investors include Cross Creek Advisors, In-Q-Tel, Digitalis Ventures, Highland Capital Partners.
- How much funding has OpGen raised?
- OpGen has disclosed $65M raised across 13 of its 14 known rounds.
- Where is OpGen headquartered?
- OpGen is headquartered in Gaithersburg, US.